NASDAQ:LMNX - Luminex Stock Price, News, & Analysis

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex announced a quarterly dividend on Friday, May 18th. Investors of record on Friday, June 22nd will be given a dividend of $0.06 per share on Friday, July 13th. This represents a $0.24 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Thursday, June 21st. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) posted its earnings results on Monday, August, 6th. The medical instruments supplier reported $0.15 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by $0.04. The medical instruments supplier earned $79.60 million during the quarter, compared to the consensus estimate of $79.66 million. Luminex had a net margin of 10.57% and a return on equity of 7.44%. The company's quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.26 EPS. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, October, 29th 2018. View Earnings Estimates for Luminex.

4 equities research analysts have issued twelve-month price targets for Luminex's stock. Their forecasts range from $22.00 to $34.00. On average, they expect Luminex's stock price to reach $27.25 in the next year. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for Luminex.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Some companies that are related to Luminex include Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Nevro (NVRO), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Cryolife (CRY), Atrion (ATRI), AtriCure (ATRC) and Tactile Systems Technology (TCMD).

Media coverage about LMNX stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Luminex earned a daily sentiment score of 0.11 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 48.94 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Luminex.

Luminex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.83%), Renaissance Technologies LLC (4.47%), Dimensional Fund Advisors LP (4.39%), RGM Capital LLC (3.88%), Acadian Asset Management LLC (3.55%) and Investment Management of Virginia LLC (2.08%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including RGM Capital LLC, Renaissance Technologies LLC, Alambic Investment Management L.P., Russell Investments Group Ltd., DAFNA Capital Management LLC, Investment Management of Virginia LLC, Point72 Asset Management L.P. and Fisher Asset Management LLC. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Insider Buying and Selling for Luminex.

LMNX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, Federated Investors Inc. PA, Spark Investment Management LLC, Schwab Charles Investment Management Inc., TD Asset Management Inc., Citadel Advisors LLC and State Board of Administration of Florida Retirement System. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $26.79.

Luminex has a market capitalization of $1.21 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]